New therapeutic vax targets multiple cancers

Investigators are reporting promising results from their early-stage trial of a new therapeutic cancer vaccine. Scientists say the new vaccine uses an alphavirus to deliver a gene for the carcinoembryonic antigen. Alphaviruses are known to naturally track down dendritic cells, a powerful stimulator of the immune system. In a small human trial involving 28 participants suffering from a variety of late-stage cancers, the vaccine was able to help five of the patients. Story